95 related articles for article (PubMed ID: 15477633)
1. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
[TBL] [Abstract][Full Text] [Related]
2. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Koeberle D; Thuerlimann B
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):55-66. PubMed ID: 17912636
[TBL] [Abstract][Full Text] [Related]
3. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
Lazar AA; Bonetti M; Cole BF; Yip WK; Gelber RD
Clin Trials; 2016 Apr; 13(2):169-79. PubMed ID: 26493094
[TBL] [Abstract][Full Text] [Related]
4. Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.
López AM; Pruthi S; Boughey JC; Perloff M; Hsu CH; Lang JE; Ley M; Frank D; Taverna JA; Chow HH
Cancer Prev Res (Phila); 2016 Feb; 9(2):142-8. PubMed ID: 26667449
[TBL] [Abstract][Full Text] [Related]
5. Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Huober J; Cole BF; Rabaglio M; Giobbie-Hurder A; Wu J; Ejlertsen B; Bonnefoi H; Forbes JF; Neven P; Láng I; Smith I; Wardley A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Gelber RD; Thürlimann B;
Breast Cancer Res Treat; 2014 Jan; 143(1):159-69. PubMed ID: 24305979
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer.
Tocaciu S; Oliver LJ; Lowenthal RM; Peterson GM; Patel R; Shastri M; McGuinness G; Olesen I; Fitton JH
Integr Cancer Ther; 2018 Mar; 17(1):99-105. PubMed ID: 28008779
[TBL] [Abstract][Full Text] [Related]
7. Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.
Symonds LK; Davidson NE
J Natl Cancer Inst; 2023 Nov; 115(11):1240-1242. PubMed ID: 37480258
[No Abstract] [Full Text] [Related]
8. Estimating efficacy in trials with selective crossover.
Brentnall AR; Sasieni P; Cuzick J
Stat Med; 2017 Jul; 36(15):2333-2346. PubMed ID: 28295486
[TBL] [Abstract][Full Text] [Related]
9. Development of Distress During a Radiotherapy Course in Patients Irradiated for Breast Cancer.
Delikanli C; Janssen S; Yu NY; Rades D
In Vivo; 2023; 37(6):2755-2759. PubMed ID: 37905616
[TBL] [Abstract][Full Text] [Related]
10. Retracted: Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma.
Methods In Medicine CAM
Comput Math Methods Med; 2023; 2023():9804628. PubMed ID: 37811251
[TBL] [Abstract][Full Text] [Related]
11. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Dombernowsky P; Smith I; Falkson G; Leonard R; Panasci L; Bellmunt J; Bezwoda W; Gardin G; Gudgeon A; Morgan M; Fornasiero A; Hoffmann W; Michel J; Hatschek T; Tjabbes T; Chaudri HA; Hornberger U; Trunet PF
J Clin Oncol; 1998 Feb; 16(2):453-61. PubMed ID: 9469328
[TBL] [Abstract][Full Text] [Related]
12. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Paridaens RJ; Dirix LY; Beex LV; Nooij M; Cameron DA; Cufer T; Piccart MJ; Bogaerts J; Therasse P
J Clin Oncol; 2008 Oct; 26(30):4883-90. PubMed ID: 18794551
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.
Smith I; Yardley D; Burris H; De Boer R; Amadori D; McIntyre K; Ejlertsen B; Gnant M; Jonat W; Pritchard KI; Dowsett M; Hart L; Poggio S; Comarella L; Salomon H; Wamil B; O'Shaughnessy J
J Clin Oncol; 2017 Apr; 35(10):1041-1048. PubMed ID: 28113032
[TBL] [Abstract][Full Text] [Related]
14. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL
J Natl Cancer Inst; 2005 Sep; 97(17):1262-71. PubMed ID: 16145047
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Ruhstaller T; Giobbie-Hurder A; Colleoni M; Jensen MB; Ejlertsen B; de Azambuja E; Neven P; Láng I; Jakobsen EH; Gladieff L; Bonnefoi H; Harvey VJ; Spazzapan S; Tondini C; Del Mastro L; Veyret C; Simoncini E; Gianni L; Rochlitz C; Kralidis E; Zaman K; Jassem J; Piccart-Gebhart M; Di Leo A; Gelber RD; Coates AS; Goldhirsch A; Thürlimann B; Regan MM;
J Clin Oncol; 2019 Jan; 37(2):105-114. PubMed ID: 30475668
[TBL] [Abstract][Full Text] [Related]
17. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
Mamounas EP; Jeong JH; Wickerham DL; Smith RE; Ganz PA; Land SR; Eisen A; Fehrenbacher L; Farrar WB; Atkins JN; Pajon ER; Vogel VG; Kroener JF; Hutchins LF; Robidoux A; Hoehn JL; Ingle JN; Geyer CE; Costantino JP; Wolmark N
J Clin Oncol; 2008 Apr; 26(12):1965-71. PubMed ID: 18332472
[TBL] [Abstract][Full Text] [Related]
18. Letrozole in advanced breast cancer: the PO25 trial.
Mouridsen HT
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):19-29. PubMed ID: 17333340
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Mouridsen H; Chaudri-Ross HA
Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
[TBL] [Abstract][Full Text] [Related]
20. The NEOLETEXE trial: a neoadjuvant cross-over study exploring the lack of cross resistance between aromatase inhibitors.
Bahrami N; Sauer T; Engebretsen S; Aljabri B; Bemanian V; Lindstrøm J; Lüders T; Kristensen V; Lorentzen A; Loeng M; Ødegård HP; Kvaløy JØ; Vestøl IB; Geisler SB; Gravdehaug B; Gundersen JM; Geisler J
Future Oncol; 2019 Nov; 15(32):3675-3682. PubMed ID: 31513453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
